Dublin, Jan. 13, 2017 -- Research and Markets has announced the addition of the "Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021" report to their offering.
The biosimilars market is expected to reach USD 10.90 Billion by 2021 from USD 3.39 Billion in 2016, at a CAGR of 26.3%.
The global biosimilars market is segmented on the basis of product, manufacturing type, and application. Factors such as rising incidence of various diseases, increasing demand for biosimilar drugs due to their cost-effectiveness, growing pressure to curtail healthcare expenditure, rising geriatric population, strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars, and increasing government support and initiatives to develop and promote biosimilars are expected to drive the growth of this market.
Emerging markets and new indications and patent expiry of biologic products has opened an array of opportunities for players in the biosimilars market. However, complexities in manufacturing and innovative strategies by biologic drug manufacturers are expected to restrain the growth of this market to a certain extent during the forecast period.
The key players in the biosimilars market include:
- Amgen Inc.
- Biocon Ltd.
- Celltrion Inc.
- Dr. Reddy's Laboratories
- F. Hoffmann-La Roche Ltd.
- Mylan Inc.
- Pfizer Inc.
- Samsung Bioepis
- Sandoz International Gmbh (A Division of Novartis International Ag)
- Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Biosimilars Market, by Type of Product
7 Biosimilars Market, by Type of Manufacturing
8 Biosimilars Market, by Application
9 Biosimilars Market, by Region
10 Competitive Landscape
11 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/kb6hn6/biosimilars
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biosimilars and Biosuperiors


MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
First Western Ship Transits Strait of Hormuz Since Iran War Began
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 



